USP32 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:84669, HGNC:19143, MIM:607740, NM_032582, NP_115971, NY-REN-60, USP10, USP32, XM_011525371, XM_011525372, XM_011525373, XM_011525374, XM_011525375, XM_011525376, XM_011525378, XM_011525379, XM_017025233, XM_017025234, XP_011523673, XP_011523674, XP_011523675, XP_011523676, XP_011523677, XP_011523678, XP_011523680, XP_011523681, XP_016880722, XP_016880723, ubiquitin specific peptidase 32

Omim:OMIM:607740

Id:31618f3e-d253-55c3-835f-925db68b4961

Hgnc:HGNC:19143

Entrez:84669

Ensembl:ENSG00000170832

Description:ubiquitin specific peptidase 32

Enables thiol-dependent deubiquitinase. Predicted to be involved in protein deubiquitination. Located in Golgi apparatus and cytosol. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View USP32's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with USP32.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using USP32.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for USP32.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with USP32.

Results found

Linked to

	Label	Description
	GSE150244 TRIM8 knockout 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE207871 NPC knockdown S18 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE147662 3 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 0 V 10 SULFORAPHANE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE171692 FXN knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 12 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228017 parthenolide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE80098 GSE80366 progesterone 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE150244 TRIM8 knockout 3 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE207871 NPC knockdown S18 1 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE147662 3 V 1 NICOTINAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 0 V 10 SULFORAPHANE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE171692 FXN knockdown 1 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 12 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE228017 parthenolide 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE80098 GSE80366 progesterone 0 v 8 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.